Hamlet Pharma has started a collaboration with the company Neurochase Ltd. to develop new technology and methods for the treatment of central nervous system (CNS) tumors with Alpha1H. Alpha1H is effective against a range of solid and hematological tumor cells that commonly metastasize to the CNS. Early studies in rats have shown that infusion of HAMLET into the brain markedly delayed the development of glioblastoma.
As a pioneer in this field, our collaborator Professor Steven Gill, founder of Neurochase Ltd., has invented new technologies for drug delivery to the brain and used them successfully in the treatment of neurological diseases and cancer. In this collaboration between Neurochase and Hamlet Pharma, new technology will be developed to deliver Alpha1H to the leptomeninges (the thin membranes that surround the brain and spinal cord, between which the cerebrospinal fluid is located) for the treatment of primary and secondary CNS tumors. The collaboration will primarily explore infusion of Alpha1H in an animal model in preparation for application to clinical trials.
The brain tumor market
Glioblastomas (GBMs) are highly invasive and malignant brain tumors with a poor prognosis, accounting for approximately 60% of all primary brain tumors. At the time of diagnosis, the tumors are mostly unavailable for complete surgical removal due to spread of tumor cells from the primary tumor site and there is a lack of effective alternative treatments.
Brain tumor diagnostics and treatment market is expected to grow from USD 832.6 million in 2020 to USD 1,254.3 million in 2026 at a CAGR of over 7.3% during the forecast period.
This indication represents a large number of patients with a great medical need for new effective and safe treatments.